CAHC’s President, Joel White, published an op-ed in The Well News on the impact of the Inflation Reduction Act’s pill penalty.
The policy specifies that Medicare should impose price controls on the most popular “biologic” drugs once they’ve been on the market for 13 years. By contrast, Medicare can impose price controls on small-molecule drugs — which typically come in pill form — once they’ve been on the market for nine years.